Decoding Disease: How the Englander Institute is transforming medicine
Here at Weill Cornell Medicine and NewYork-Presbyterian Hospital we are changing the face of how we diagnose, treat, and care for patients using a more personalized approach, called precision medicine.
What is precision medicine? It's targeted, individualized care that is tailored to each patient based on his or her specific genetic profile and medical history. Unlike in traditional one-size-fits-all medicine, practitioners of precision medicine use genomic sequencing tools to interrogate a patient’s entire genome to locate the specific genetic alterations that have given rise to and are driving his or her tumor. With this information they can identify small molecule drugs, monoclonal antibodies, vaccines, and other therapies that are most precisely targeted and are therefore most effective and have the fewest side effects.
We work closely with the Meyer Cancer Center to ensure our patients are benefitting from cutting-edge research, which is also helping to drive our mission of discovery and care as well.
Our institutional priorities include the development of a centralized procedure for evaluating the molecular changes (genetic, epigenetic, gene expression) associated with both solid tumors and hematologic malignancies. Genomic analyses of tumor tissue will enable researchers to identify treatments for patients with advanced disease and no existing treatment options, as well as to determine the mechanisms of drug resistance in patients who stop responding to treatments, redirecting them to more successful therapies. Discovery based on such genomic analyses will be central to the development of novel, personalized therapies based on the unique genetic tumor profile and will lead to evaluation of new drugs in innovative clinical trials.